Literature DB >> 10422763

Plasma endothelin levels and vascular responses at different temporal stages of streptozotocin diabetes.

R L Hopfner1, J R McNeill, V Gopalakrishnan.   

Abstract

While alterations in the release and action of endothelial derived vasoactive factors such as endothelin- and endothelial derived relaxing factor (EDRF) occur in diabetes mellitus, the nature and direction of these changes is controversial. We examined the role of diabetes duration on endothelin- plasma levels and vasoconstrictor responses to endothelin-1 in aortic rings from streptozotocin-induced diabetic rats. Endothelin-1 plasma levels were attenuated at 2-weeks, but conversely elevated at 14-weeks, after diabetes induction. Similarly, maximal vasoconstriction to endothelin-1 in aorta was exaggerated in 2-week, but attenuated in 14-week diabetic rats. Also, sensitivity of aorta to endothelin-1 was enhanced in the 14-week group. Neither nitric oxide synthase inhibition with nitro-L-arginine-methyl-ester, nor endothelium removal affected alterations in maximal vasoconstriction, but both abolished changes in sensitivity to endothelin-1. Endothelium dependent (acetylcholine-evoked) vasorelaxation responses were attenuated in 14-week, but not 2-week, diabetic rats, while endothelium independent (sodium nitroprusside-evoked) responses remained unchanged. Together, these data indicate a deficiency in EDRF production in the 14-week group. Elevated plasma glucose and attenuated insulin levels were present in both groups, but plasma cholesterol and triglyceride levels were elevated only in 14-week rats. We conclude that differences in the pre-existing duration of diabetes differentially affect both plasma levels and action of endothelin-1. These changes might be linked to coincident diabetes duration dependent changes in EDRF production and plasma lipid levels. Such a shift in the production and action of endothelial derived relaxing and contracting factors might contribute to the characteristic early and late stage cardiovascular complications of diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10422763     DOI: 10.1016/s0014-2999(99)00316-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Endothelin-1 receptor blockade prevented the electrophysiological dysfunction in cardiac myocytes of streptozotocin-induced diabetic rats.

Authors:  Yanfeng Ding; Ruijiao Zou; Robert L Judd; Juming Zhong
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

2.  Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature.

Authors:  L Rodríguez-Mañas; J Angulo; S Vallejo; C Peiró; A Sánchez-Ferrer; E Cercas; P López-Dóriga; C F Sánchez-Ferrer
Journal:  Diabetologia       Date:  2003-03-12       Impact factor: 10.122

3.  Endothelin-1 Overexpression Exaggerates Diabetes-Induced Endothelial Dysfunction by Altering Oxidative Stress.

Authors:  Noureddine Idris-Khodja; Sofiane Ouerd; Muhammad Oneeb Rehman Mian; Jordan Gornitsky; Tlili Barhoumi; Pierre Paradis; Ernesto L Schiffrin
Journal:  Am J Hypertens       Date:  2016-11-01       Impact factor: 2.689

4.  Exercise Training and Grape Seed Extract Co-Administration Improves Lipid Profile, Weight Loss, Bradycardia, and Hypotension of STZ-Induced Diabetic Rats.

Authors:  Mohammad Badavi; Hassan Ali Abedi; Mahin Dianat; Ali Reza Sarkaki
Journal:  Int Cardiovasc Res J       Date:  2013-12-01

5.  Aminoguanidine inhibits aortic hydrogen peroxide production, VSMC NOX activity and hypercontractility in diabetic mice.

Authors:  Jeong-Ho Oak; Ji-Youn Youn; Hua Cai
Journal:  Cardiovasc Diabetol       Date:  2009-12-30       Impact factor: 9.951

6.  Retinal blood flow dysregulation precedes neural retinal dysfunction in type 2 diabetic mice.

Authors:  Junya Hanaguri; Harumasa Yokota; Masahisa Watanabe; Satoru Yamagami; Akifumi Kushiyama; Lih Kuo; Taiji Nagaoka
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.